DK0475291T3 - Fra kylling afledt biologisk aktivt peptid (kylling CNP) - Google Patents

Fra kylling afledt biologisk aktivt peptid (kylling CNP)

Info

Publication number
DK0475291T3
DK0475291T3 DK91115080T DK91115080T DK0475291T3 DK 0475291 T3 DK0475291 T3 DK 0475291T3 DK 91115080 T DK91115080 T DK 91115080T DK 91115080 T DK91115080 T DK 91115080T DK 0475291 T3 DK0475291 T3 DK 0475291T3
Authority
DK
Denmark
Prior art keywords
chicken
biologically active
cnp
active peptide
derived biologically
Prior art date
Application number
DK91115080T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Hisayuki Matsuo
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisayuki Matsuo, Suntory Ltd filed Critical Hisayuki Matsuo
Application granted granted Critical
Publication of DK0475291T3 publication Critical patent/DK0475291T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91115080T 1990-09-07 1991-09-06 Fra kylling afledt biologisk aktivt peptid (kylling CNP) DK0475291T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238293A JP2977158B2 (ja) 1990-09-07 1990-09-07 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）

Publications (1)

Publication Number Publication Date
DK0475291T3 true DK0475291T3 (da) 1999-08-30

Family

ID=17028039

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91115080T DK0475291T3 (da) 1990-09-07 1991-09-06 Fra kylling afledt biologisk aktivt peptid (kylling CNP)

Country Status (8)

Country Link
US (1) US5338830A (da)
EP (1) EP0475291B1 (da)
JP (1) JP2977158B2 (da)
AT (1) ATE175210T1 (da)
DE (1) DE69130696T2 (da)
DK (1) DK0475291T3 (da)
ES (1) ES2127190T3 (da)
GR (1) GR3029628T3 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
CN1960758B (zh) 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
EP1743653A4 (en) 2004-03-31 2009-09-30 Kazuwa Nakao COMPOSITION FOR INCREASING BODY SIZE
EP1759001B1 (en) 2004-04-21 2011-04-13 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
WO2017022728A1 (ja) * 2015-07-31 2017-02-09 株式会社イギス Ｃｎｐ環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
EP4291224A1 (en) 2021-02-12 2023-12-20 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DE69130696D1 (de) 1999-02-11
JP2977158B2 (ja) 1999-11-10
EP0475291B1 (en) 1998-12-30
DE69130696T2 (de) 1999-06-10
JPH04120094A (ja) 1992-04-21
EP0475291A1 (en) 1992-03-18
ATE175210T1 (de) 1999-01-15
GR3029628T3 (en) 1999-06-30
ES2127190T3 (es) 1999-04-16
US5338830A (en) 1994-08-16

Similar Documents

Publication Publication Date Title
DK0475291T3 (da) Fra kylling afledt biologisk aktivt peptid (kylling CNP)
GR3029632T3 (en) A novel biologically active peptide derived from frog (frog CNP)
FI924453A (fi) Nya 9-amino-7-(substituerad)-6-demetyl-6-deoxitetracykliner
DE69020794D1 (de) Enzymatische Entfernung einer aminoterminalen Proteinsequenz.
FI924454A (fi) Nya 7-substituerad-9-(substituerad amino)-6-demetyl-6-deoxitetracykliner
DE69219590D1 (de) BPC-Peptide, deren Herstellung und Verwendung
NO895028D0 (no) Ny chimerisk transformerende vekstfaktor-beta.
ES2108016T3 (es) Triazolopiridazinas substituidas.
HUT51295A (en) Process for producing peptidalcohol derivatives of anticoagulant activity
DK38889D0 (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
ATE47880T1 (de) Vorlaeufer eines an dem c-ende amidierten peptids und dessen herstellung.
ATE305044T1 (de) Lgmd- gen kodierend für einer calcium abhängigen protease
FR2520740B1 (da)
DE3689008D1 (de) Verfahren zur Herstellung und Reinigung von alpha-Interferon.
ATE130630T1 (de) Sg(beta)-1,4-galaktanase und dns-sequenz.
ATE133709T1 (de) Peroxidase-gen von mikrobischem ursprung
ES2079054T3 (es) Peptidilhidroxiglicina n-c-liasa y adn codificante de la misma.
DE59602774D1 (de) Verfahren zur Herstellung von 3.3.5-Trimethylcyclohexanon
DK0453719T3 (da) Bacteriocinpeptid
ES2059766T3 (es) Precursor de prostaglandinas y su produccion.
FR2551088B1 (da)
EP1295943A4 (en) POLYPEPTIDES CAPABLE THE POWER TO STIMULATE NEUTROPHILES
ATE37865T1 (de) Verfahren zur herstellung von monochloressigsaeure aus glykolsaeure.
ATE102997T1 (de) Thymosin und tnf-kodierende dna.
DE3876788D1 (de) Erzeugnis, enthaltend als wirkstoffe: a) ein peptid mit einer wirkung von der art des gamma-hu-interferons b) hydroxyharnstoff.